Article Text
PDFPapers
Small therapeutic molecules for the treatment of inflammatory bowel disease
Abstract
New therapies for inflammatory bowel disease are needed, because standard therapies fail to induce remission in about 30% of patients, and because of the relative inefficacy of current maintenance therapies. This review summarises the current status of the development of small therapeutic molecules for inflammatory bowel disease.
- inlammatory bowel disease
- eocosanoid
- nitric oxide
- phosphodiesterase
- thalidomide
- COX, cyclooxygenase
- CREB, cAMP response element binding protein
- IFN, interferon
- IL, interleukin
- JNK, c-JUN NH2 terminal kinase
- LPS, lipopolysaccharide
- LT, leukotriene
- MAP, mitogen activated protein
- NF, nuclear factor
- NO, nitric oxide
- NSAID, non-steroidal anti-inflammatory drug
- PAF, platelet activating factor
- PDE, phosphodiesterase
- PPAR, peroxisome proliferator activated receptor
- SAPK, stress activated MAP kinase
- TACE, TNFα converting enzyme
- TNBS, trinitro-benzene-sulphonic acid
- TNFα, tumour necrosis factor α
Statistics from Altmetric.com
- COX, cyclooxygenase
- CREB, cAMP response element binding protein
- IFN, interferon
- IL, interleukin
- JNK, c-JUN NH2 terminal kinase
- LPS, lipopolysaccharide
- LT, leukotriene
- MAP, mitogen activated protein
- NF, nuclear factor
- NO, nitric oxide
- NSAID, non-steroidal anti-inflammatory drug
- PAF, platelet activating factor
- PDE, phosphodiesterase
- PPAR, peroxisome proliferator activated receptor
- SAPK, stress activated MAP kinase
- TACE, TNFα converting enzyme
- TNBS, trinitro-benzene-sulphonic acid
- TNFα, tumour necrosis factor α